Remove Cardiology Remove Genetic Disease Remove Genetics
article thumbnail

BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CM

XTalks

BridgeBio has been highly active in the genetic diseases space. Its investigational therapy infigratinib recently received Breakthrough Therapy designation, becoming the first-ever potential treatment for achondroplasia — a genetic condition affecting bone growth — to achieve this milestone.

article thumbnail

FSU College of Medicine researcher develops new possibilities to prevent sudden cardiac death

Scienmag

A leading cause of SCD in young athletes is arrhythmogenic cardiomyopathy (ACM), a genetic disease in which healthy heart muscle is replaced over time […]. Credit: Mark Bauer/FSU College of Medicine Nearly a half-million people a year die from sudden cardiac death (SCD) in the U.S.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

Dr. Benoit Tyl, MD, FESC, medical and scientific director, cardiology at Servier, says that the disconnect between correlation and causality in cardiovascular disease trials is partially responsible for the lack of approved HFpEF therapies. Figure 1: The use of Mendelian randomization to validate genetic drug targets.